Some would say that when the manager of biostatistics of a multi-billion-dollar pharmaceutical corporation tells you that there is something wrong with the data you’re using to bring a drug to market, you might want to listen to that person. However, if allegations in a new lawsuit against GlaxoSmithKline are proven true, the other option is to try to get away with firing the biostatistician and move on.
Such are ...
continue reading...